Study of Rifaximin in Minimal Hepatic Encephalopathy

Completed · Phase 1/Phase 2

Conditions studied: Minimal Hepatic Encephalopathy

In brief

Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.

Key facts

Study ID

NCT01069133

Run by

Hunter Holmes Mcguire Veteran Affairs Medical Center

People needed

20

Starts

2010-02-01

Expected to finish

2012-12-01

Last updated by the study team

2012-12-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-65 years
• cirrhosis diagnosed by clinical or biopsy grounds
• Minimal hepatic encephalopathy defined by impaired performance on at least 2 of the following: number connection tests A/B, digit symbol and block design tests (NCT-A, NCT-B, DST and BDT) compared to age and education-matched controls.
• No contraindications to MRI
• TIPS (transjugular intra-hepatic porto-systemic shunt) procedure or elective surgery planned within the next 8 weeks

You may not qualify if…

• Current therapy with lactulose, rifaximin or other treatment for hepatic encephalopathy.
• Prior episodes of overt HE
• MMSE <25
• TIPS placement
• Unable to give informed consent.
• Contra-indications to MRI

Where it is running

• Hunter Holmes McGuire VA Medical Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.